MedPath

The Efficacy of Combination of Traditional Tibetan and Remote Ischemic Conditioning on High Altitude Polycythemia

Phase 2
Not yet recruiting
Conditions
High Altitude Polycythemia
Interventions
Drug: Tibetan Medicine (Shiliu Jianwei Powder, Ershiwuwei Yuganzi Pills, Qiwei Tiexue Pill)
Device: Remote Ischemic Conditioning
Registration Number
NCT06082583
Lead Sponsor
Capital Medical University
Brief Summary

A multicenter, randomized controlled trial was designed to evaluate the effectiveness and safety of the comprehensive traditional Tibetan medicine program combined with remote ischemic conditioning on high altitude polycythemia.

Detailed Description

Not available

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
300
Inclusion Criteria
  • Patients with high-altitude polycythemia aging 18 to 65 years.
Exclusion Criteria
  • Allergic to Tibetan medicine ingredients;
  • Inappropriate to receive Tibetan medicine treatment and/or remote ischemic conditioning.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Tibetan Medicine GroupTibetan Medicine (Shiliu Jianwei Powder, Ershiwuwei Yuganzi Pills, Qiwei Tiexue Pill)-
Tibetan Medicine-Remote Ischemic Conditioning GroupRemote Ischemic Conditioning-
Tibetan Medicine-Remote Ischemic Conditioning GroupTibetan Medicine (Shiliu Jianwei Powder, Ershiwuwei Yuganzi Pills, Qiwei Tiexue Pill)-
Primary Outcome Measures
NameTimeMethod
The incidence of effective treatmentBaseline and 1 month after treatment.

The hemoglobin levels decreased ≥20% after treatment compared to pre-treatment.

Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath